This phase 2 study investigated ramucirumab in combination with first–line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC.
READ FULL ARTICLE
From Mdlinx
According to a new study published in the journal Cancer, researchers have found that ramucirumab demonstrated clinical activity in combination with pemetrexed plus carboplatin or cisplatin in patients with nonsquamous non-small cell lung cancer (NSCLC).
Researchers randomly assigned participants to receive pemetrexed plus carboplatin or cisplatin with or without ramucirumab 10mg/kg once every 3 weeks for four to six cycles, followed by a maintenance phase with pemetrexed with or without ramucirumab.
Results showed a median progression-free survival of 5.6 months for patients who received pemetrexed plus platinum versus 7.2 months for those who received pemetrexed, platinum, and ramucirumab (HR = 0.75; P = 0.132). Patients in the pemetrexed-platinum arm had a objective response rate of 38.0% compared with 49.3% in the ramucirumab arm (P = 0.180).
The disease control rate was 70.4% and 85.5% for the pemetrexed-platinum and ramucirumab arms, respectively (P = 0.032). The most common grade 3 or higher adverse effects were anemia, back pain, fatigue, hypertension, neutropenia, and thrombocytopenia. Ultimately, the primary endpoint of progression-free survival was not met.
This phase 2 study investigated ramucirumab in combination with first–line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC.
READ FULL ARTICLE
From Mdlinx
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.